Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedFeb 06, 2025
DataAggregated Company Financials
Companies11
- 7D-1.8%
- 3M8.3%
- 1Y-54.9%
- YTD3.5%
Over the last 7 days, the Biotech industry has dropped 1.8%, driven by a pullback from Hofseth BioCare of 6.1%. On the other hand EXACT Therapeutics is actually up 17%. The industry has fallen 55% in the last year. As for the next few years, earnings are expected to grow by 23% per annum.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 06 Feb 2025 | NOK 5.1b | NOK 457.0m | -NOK 1,120,111,619.96 | 159.8x | -4.6x | 11.2x |
| Sat, 04 Jan 2025 | NOK 4.7b | NOK 457.7m | -NOK 1,074,631,101.08 | 155.2x | -4.4x | 10.4x |
| Mon, 02 Dec 2024 | NOK 4.3b | NOK 456.2m | -NOK 1,061,738,631.68 | 140.6x | -4x | 9.4x |
| Wed, 30 Oct 2024 | NOK 4.7b | NOK 472.2m | -NOK 1,071,223,181.00 | 62.3x | -4.4x | 10x |
| Fri, 27 Sep 2024 | NOK 5.0b | NOK 469.4m | -NOK 1,048,341,304.20 | 61.8x | -4.7x | 10.6x |
| Sun, 25 Aug 2024 | NOK 6.2b | NOK 467.8m | -NOK 1,044,082,311.10 | 73.3x | -5.9x | 13.2x |
| Tue, 23 Jul 2024 | NOK 8.8b | NOK 517.3m | -NOK 1,054,574,405.20 | 71.4x | -8.4x | 17.1x |
| Thu, 20 Jun 2024 | NOK 9.0b | NOK 640.9m | -NOK 938,387,919.58 | 39.4x | -9.6x | 14.1x |
| Sat, 18 May 2024 | NOK 8.8b | NOK 631.9m | -NOK 989,548,946.58 | 31.8x | -8.9x | 13.9x |
| Mon, 15 Apr 2024 | NOK 8.6b | NOK 659.2m | -NOK 946,124,130.08 | 39.5x | -9.1x | 13.1x |
| Wed, 13 Mar 2024 | NOK 9.3b | NOK 654.0m | -NOK 932,317,060.18 | 41.8x | -10x | 14.3x |
| Fri, 09 Feb 2024 | NOK 14.9b | NOK 659.4m | -NOK 1,053,371,655.56 | 42x | -14.1x | 22.6x |
| Sun, 07 Jan 2024 | NOK 16.4b | NOK 654.3m | -NOK 1,352,819,123.00 | 59.2x | -12.2x | 25.1x |
| Tue, 05 Dec 2023 | NOK 14.9b | NOK 662.1m | -NOK 1,375,416,454.00 | 59.2x | -10.9x | 22.6x |
| Thu, 02 Nov 2023 | NOK 13.2b | NOK 491.9m | -NOK 1,561,354,786.00 | 100.9x | -8.5x | 26.9x |
| Sat, 30 Sep 2023 | NOK 15.3b | NOK 623.9m | -NOK 1,452,898,817.00 | 56.9x | -10.5x | 24.5x |
| Mon, 28 Aug 2023 | NOK 15.4b | NOK 627.5m | -NOK 1,436,001,990.00 | 58.7x | -10.7x | 24.5x |
| Wed, 26 Jul 2023 | NOK 16.3b | NOK 554.1m | -NOK 1,447,940,351.00 | 60.2x | -11.2x | 29.4x |
| Fri, 23 Jun 2023 | NOK 15.6b | NOK 560.5m | -NOK 1,473,963,571.00 | 58x | -10.6x | 27.9x |
| Sun, 21 May 2023 | NOK 16.8b | NOK 562.1m | -NOK 1,494,152,506.00 | 61.3x | -11.2x | 29.9x |
| Tue, 18 Apr 2023 | NOK 16.7b | NOK 549.5m | -NOK 1,553,053,500.00 | 30.7x | -10.8x | 30.4x |
| Thu, 16 Mar 2023 | NOK 15.1b | NOK 538.9m | -NOK 1,568,307,531.00 | 29.5x | -9.7x | 28.1x |
| Sat, 11 Feb 2023 | NOK 18.7b | NOK 805.9m | -NOK 1,413,726,163.00 | 33.2x | -13.2x | 23.1x |
| Mon, 09 Jan 2023 | NOK 18.3b | NOK 812.8m | -NOK 1,396,278,123.00 | 29.6x | -13.1x | 22.5x |
| Wed, 07 Dec 2022 | NOK 18.4b | NOK 811.7m | -NOK 1,395,709,793.00 | 37.2x | -13.2x | 22.7x |
| Fri, 04 Nov 2022 | NOK 17.4b | NOK 808.7m | -NOK 1,366,424,014.00 | 36.4x | -12.7x | 21.5x |
| Sun, 02 Oct 2022 | NOK 16.3b | NOK 823.6m | -NOK 1,367,968,157.00 | 36.4x | -11.9x | 19.8x |
| Tue, 30 Aug 2022 | NOK 20.1b | NOK 783.3m | -NOK 1,377,576,989.00 | 36.8x | -14.6x | 25.6x |
| Thu, 28 Jul 2022 | NOK 19.6b | NOK 768.4m | -NOK 1,380,660,609.00 | 43.4x | -14.2x | 25.5x |
| Sat, 25 Jun 2022 | NOK 19.9b | NOK 769.5m | -NOK 1,380,979,565.00 | 43.1x | -14.4x | 25.9x |
| Mon, 23 May 2022 | NOK 22.7b | NOK 1.1b | -NOK 1,034,032,765.00 | 37.6x | -22x | 20.8x |
| Wed, 20 Apr 2022 | NOK 25.6b | NOK 1.0b | -NOK 985,984,960.00 | 43.6x | -26x | 24.7x |
| Fri, 18 Mar 2022 | NOK 25.4b | NOK 2.7b | NOK 398.1m | 9.2x | 63.8x | 9.5x |
| Sun, 13 Feb 2022 | NOK 29.6b | NOK 2.7b | NOK 447.4m | 11x | 66.2x | 11.1x |
Price to Earnings Ratio
66.2x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 20.5x is higher than the industry's current PS ratio of 11.2x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 45% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the Norwegian Healthcare industry?
| NO Market | -0.75% | |
| Healthcare | -0.04% | |
| Biotech | -1.80% | |
| Biotech | -1.80% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| EXTX EXACT Therapeutics | NOK 4.02 | 24.8% +NOK 50.6m | -66.5% | PB14.6x | |
| BGBIO BerGenBio | NOK 8.24 | 3.2% +NOK 10.0m | -72.8% | PS618.2x | |
| LYTIX Lytix Biopharma | NOK 5.66 | 2.2% +NOK 8.2m | -19.7% | PS35.9x | |
| PCIB PCI Biotech Holding | NOK 1.29 | 5.7% +NOK 2.6m | -34.3% | PS8.1x |